Company Overview and News

to your dashboard

Headline News

Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion

7h zacks
Pfizer Inc. (PFE - Free Report) announced that the FDA has approved a label expansion for its janus kinase (JAK) inhibitor, Xeljanz (tofacitinib), for two doses — 5 mg twice daily and 11 mg once-daily extended-release (XR) formulation. (156-0)

Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA

8h zacks
Bristol-Myers Squibb Company (BMY - Free Report) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for priority review of Opdivo plus Yervoy (ipilimumab) for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). (120-0)

My Journey To Financial Independence: 86-Stock November Portfolio Update - Buying Apple, AbbVie And BMW

11h seekingalpha
The euro stabilized in November and my two biggest positions Altria and AT&T started to rally. (319-1)

Pfizer's Second Biosimilar of Remicade Receives FDA Approval

2017-12-14 zacks
Pfizer Inc. (PFE - Free Report) announced that the FDA has approved Ixifi its second biosimilar version of Johnson & Johnson's (JNJ - Free Report) blockbuster rheumatoid arthritis (“RA”) drug, Remicade (infliximab). Notably, Ixifi is a chimeric human-murine monoclonal antibody against tumor necrosis factor. (88-0)

More Positives For Roche, The Core Biotech For The Long Run

2017-12-14 seekingalpha
Biotech and diagnostics company Roche provided several pieces of new or more detailed data over the past month, yet the stock just sits there. (150-0)

Biotech Analysis Central Pharma News: AbbVie And Roche Stellar Data, Aduro Pulls The Cord, Allergan's Bargain Bin Buy

2017-12-14 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (174-0)

Argenx: This ASH Winner Has Further Upside Ahead

2017-12-13 seekingalpha
This ¨pipeline in a product¨ has upside in other indications as well and data in MG bodes well for future readouts. (67-0)

Roche/AbbVie Report Positive Phase III Results on Venclexta

2017-12-13 zacks
Roche Holdings AG (RHHBY - Free Report) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). (140-0)

Why Tech Still Looks So Attractive

2017-12-13 seekingalpha
ETFs, favorites of small investors, have seen investors shy away from tech even as it has led the market up. (631-2)

Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

2017-12-12 zacks
Bristol-Myers Squibb Company (BMY - Free Report) announced positive data from phase II study, CA180-372, on Sprycel. (123-0)

Novartis Announces Positive Data on Sickle Cell Disease Drug

2017-12-12 zacks
Novartis AG (NVS - Free Report) announced positive results from a post hoc subgroup analysis of the phase II study, SUSTAIN on pipeline candidate, crizanlizumab. (77-1)

Short Sellers Can’t Make Up Their Minds on Major Pharma

2017-12-12 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside. (222-1)

Buy Celgene And Regeneron On The Dips As Insiders Are Buying

2017-12-12 seekingalpha
According to SEC Form 4 filings, Celgene and Regeneron insiders bought sizable amounts of shares during the sell-offs as valuations became attractive. (163-0)

Biotech Analysis Central Pharma News: Madrigal's NASH Success, AbbVie's Phase 3 Win, Juno's Collaboration

2017-12-06 seekingalpha
AbbVie achieves positive phase 3 results in its fourth study using risankizumab in treating patients with psoriasis. (172-3)

Buy Biotech ETF IBB And Trim Semiconductor Stocks

2017-12-06 seekingalpha
The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which tracks the Nasdaq Biotechnology Index (NASDAQ:NBI), has been in and out of bear market territory, defined as a drop of 20% or more from its peak, since September 2015 when then-Presidential candidate Hillary Clinton sent out a tweet about "outrageous" price gouging by Martin Shkreli, former-CEO of Turing Pharmaceuticals. In fact, IBB was in a deep bear market for almost the entirety of 2016 because the hot issue of high prescription drug prices was an attention-getting campaign topic. (154-1)